Abbott Laboratories (ABT) Total Debt (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Total Debt data on file, last reported at $34.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 157.11% year-over-year to $34.0 billion; the trailing twelve-month figure through Mar 2026 stood at $34.0 billion (up 157.11% YoY), and the FY2025 full-year result was $12.9 billion, down 8.47% from the prior year.
• Total Debt advanced to $34.0 billion in Q1 2026, from $12.9 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $34.0 billion in Q1 2026 to a low of $12.9 billion in Q4 2025.
• A 5-year average of $16.2 billion and a median of $15.0 billion in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt dropped 13.69% in 2024 and soared 157.11% in 2026, its largest moves.
• Tracing ABT's Total Debt over 5 years: stood at $16.8 billion in 2022, then retreated by 12.48% to $14.7 billion in 2023, then declined by 3.77% to $14.1 billion in 2024, then decreased by 8.47% to $12.9 billion in 2025, then soared by 163.34% to $34.0 billion in 2026.
• Business Quant data shows ABT's Total Debt at $34.0 billion in Q1 2026, $12.9 billion in Q4 2025, and $12.9 billion in Q3 2025.